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Abstract
Background: Palliative care has been proposed to help meet the needs of patients who suffer
progressive non-cancer conditions but there have been few evaluations of service development
initiatives. We report here a novel protocol for the evaluation of a new palliative care service in
this context.
Methods/Design: Using the MRC Framework for the Evaluation of Complex Interventions we
modelled a new palliative care and neurology service for patients severely affected by Multiple
Sclerosis (MS). We conducted qualitative interviews with patients, families and staff, plus a
literature review to model and pilot the service. Then we designed a delayed intervention
randomised controlled trial to test its effectiveness as part of phase II of the MRC framework.
Inclusion criteria for the trial were patients identified by referring clinicians as having unresolved
symptoms or psychological concerns. Referrers were advised to use a score of greater than 8 on
the Expanded Disability Scale was a benchmark. Consenting patients newly referred to the new
service were randomised to either receive the palliative care service immediately (fast-track) or
after a 12-week wait (standard best practice). Face to face interviews were conducted at baseline
(before intervention), and at 4–6, 10–12 (before intervention for the standard-practice group), 16–
18 and 22–24 weeks with patients and their carers using standard questionnaires to assess
symptoms, palliative care outcomes, function, service use and open comments. Ethics committee
approval was granted separately for the qualitative phase and then for the trial.
Discussion: We publish the protocol trial here, to allow methods to be reviewed in advance of
publication of the results. The MRC Framework for the Evaluation of Complex Interventions was
helpful in both the design of the service, methods for evaluation in convincing staff and the ethics
committee to accept the trial. The research will provide valuable information on the effects of
palliative care among non-cancer patients and a method to evaluate palliative care in this context.
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Palliative care services have traditionally focussed on car-
ing for patients with cancer. In the UK, 95% of patients
cared for by in-patient hospice and home care services
have cancer; this percentage is similar in many other
countries. However, cancer accounts for only 1 in 4
deaths, and most non-cancer deaths are from conditions
where patients experience a progressive, fluctuating or
chronic condition [1,2]. The symptoms experienced in far
advanced heart failure, respiratory failure, progressive
neurological conditions, HIV/AIDS and renal failure have
much in common with those of cancer, suggesting that
palliative care services might have a role[3,4]. However,
there is no clear model of services to follow for these con-
ditions, and most evidence of effectiveness of palliative
care treatments and services relates to patients with can-
cer. Thomas and McMahon proposed a model in progres-
sive non-cancer focussed on end of life care[5,6], whereas
Skilbeck and Payne suggested specialist palliative care
should be viewed as a service for those with complex
symptoms or problems, especially at the end of life[7].
Whatever model is developed[8,9], palliative care services
in non-cancer need development and tested in robust
studies.
We therefore designed a study to develop and evaluate a
new palliative care service for people severely affected by
multiple sclerosis (MS) (both people with MS and their
families/carers), closely linked to an established MS serv-
ice run by neurologists and MS nurses. We focussed on
multiple sclerosis because it is a chronic disease affecting
the central nervous system affecting over 2.5 million peo-
ple worldwide, and is the commonest cause of neurologi-
cal disability in adults under 60 years[10]. It is associated
with a wide spectrum of physical symptoms, including
loss of function of limbs and in many instances bladder
and bowel dysfunction, pain, spasms, swallowing and
communication and cognitive difficulties, many of which
are as severe as among patients with cancer[11,12]. In
addition, MS may have profound emotional conse-
quences for those affected, including disbelief, devasta-
tion, loss, forced life choices, sadness and in some
instances depression and family conflict[13]. It often
involves complex services and treatment choices. For
some the life span with MS is unaltered. However around
20% of those affected have a progressive course from the
outset (primary progressive MS), and a further 35%
develop a progressive course following several years of
relapsing and remitting disease (secondary progressive
MS)[14,15]. For these individuals treatment options to
delay or prevent further disability are currently very lim-
ited[16,17]. Rehabilitation offers much in the way of
improving and maintaining function, activities and sup-
port[18]. The severity of symptoms and psychological dis-
tress of the progressive course has raised questions as to
whether some people would benefit from the addition of
specialist palliative care. Therefore, this study aimed to
develop and evaluate a new palliative care service, inte-
grated with existing MS, nursing and rehabilitation serv-
ices for people severely affected by MS.
We present the protocol of the intervention and trial
because we wish to describe the intervention and study,
both to ensure independence of the results and to stimu-
late criticism and suggestions from the journal readers.
We are aware of the challenges of evaluative design of pal-
liative care services, in particular the use of randomised
controlled trials[19,20], and the need for new methods,
and we believe that lessons learned from developing this
protocol will add to knowledge in the field.
Methods/Design
Primary aim
1. To determine whether a new palliative care and neurol-
ogy service for people severely affected by MS improves
outcomes, including symptoms and psychosocial sup-
port.
Secondary aims
1. To describe the nature of people who were referred to
the service and their symptoms and problems
2. To determine whether there are any changes over time
in symptom control, psychosocial concerns, information
provision and services received
3. To identify those aspects of the service which are most
useful to people with MS, their informal carers and health
care professionals
4. To provide methods for future phase III evaluation of
appropriate palliative care for people with MS.
Design
The development and evaluation of a new palliative care
service for people severely affected by MS was conducted
using the Medical Research Council (MRC) Framework
for the Evaluation of Complex Interventions[21,22]. This
approach has been used to develop and evaluate a wide
variety of treatments, services and public health interven-
tions, including prevention approaches which require
behaviour change, information services, educational pro-
grammes, integrated systems of patient care and comple-
mentary therapies[22]. The MRC framework follows the
approach of pre-clinical – phase IV clinical trials, see fig-
ure 1[21,22]. Although the diagram appears linear, recent
work suggests that often there is iteration between the
phases. In this study we aimed to complete the first three
phases, from pre-clinical phases to phase II (exploratory
trial).Page 2 of 11
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A multidisciplinary Project Advisory Committee (PAC)
was established for the duration of the project. This had a
lay chair, appointed by the funding body, who was a carer
of a person severely affected with MS. The PAC also
included representatives of the funding body, people
affected by MS, clinical staff, nurses, doctors, researchers
and others working in MS and related fields. The speciali-
ties of neurology, rehabilitation medicine and palliative
medicine were represented on the PAC, as were local serv-
ices that linked with the new palliative care service, and
experts who had developed services for people more
severely affected by MS in other parts of the country. The
PAC met regularly and also made contact by e-mail and
telephone with the project team.
Setting
Regional care of patients with neurological diseases was
organised through the Regional Neurosciences Centre for
Southeast London based at King's College Hospital
(KCH), where the new service was located. This Centre is
the second largest regional neuroscience centre in the UK
and serves an estimated population of 3.5 million people,
both rural and urban and from diverse ethnic back-
grounds. Patients with MS access specialist services largely
through hospitals, with five out of six boroughs in the
project also having established MS nurse specialists. The
area has a network of palliative care services, including in-
patient hospices, community services and hospital sup-
port teams, co-ordinated through the South London Pal-
liative Care Network and other regionally based networks.
Intervention design: theoretical and modelling (phases 0-I 
MRC framework)
The intervention design and modelling involved: (1)
establishing a theoretical basis by reviewing (in published
and unpublished literature and textbooks) the problems
faced by MS patients and their families/carers and of
approaches that had proved successful in related fields,
such as cancer palliative care, chronic disease and rehabil-
itation; (2) qualitative interviews with 23 people severely
affected by MS, 8 carers/family members of these individ-
uals and a further 9 carers where patients were not inter-
viewed (because patients were too ill to be interviewed
and in one instance the patient had died); and (3) twelve
focus groups and five face-to-face interviews with relevant
The MRC framework for the evaluation of complex interventionsFigure 1
The MRC framework for the evaluation of complex interventions.
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in primary care, care homes, neurology and rehabilitation
medicine, palliative care and hospices, including a range
of medical, nursing, and physiotherapy and occupational
therapy staff. The interviews and focus groups used a qual-
itative approach. Topic guides asked about the most
important concerns for people living with MS, the needs
of their carers and the problems faced by staff. The results
from this work led to the modelling of the service[23,24]
Randomised controlled trial (phase II)
The benefits and difficulties of experimental and quasi-
experimental trial designs were appraised (see figure 1 and
table 1). In doing this we were concerned about the ethics
of withholding a potentially valuable service that had
been publicised to a group of patients with advanced dis-
ease and often unmet needs. After considerable debate
and review of the likely effects of the service it was agreed
that a delayed intervention randomised controlled trial
was the best option because it provided a randomised
control trial method. All patients were likely to receive the
service, given their probable survival. Thus patients were
randomised to either receive the intervention immedi-
ately (fast track) or to receive standard best practice alone
for three months and then be offered the intervention
(standard best practice). If staff and the consultant screen-
ing the referral deemed that patients had very urgent
needs or were deteriorating rapidly, then immediate refer-
ral to the service was possible, and patients did not enter
the trial. Reasons for immediate referral, refusal and other
reasons for not entering the trial were recorded.
Randomisation
The randomisation was conducted independently by sta-
tistical colleagues after the baseline interview, independ-
ent of the research and clinical team, using the
minimisation method[25] to give an equal balance
between groups of the following: gender, age, and date of
diagnosis and according to whether patients could or
could not communicate. The minimisation method
ensures a balanced distribution of selected potentially
prognostic factors even in small trials, such as this
one[25].
Recruitment, consent and baseline interviews
A consultant in palliative medicine (PE or IJH) not part of
the service initially screened all referrals. Patients were
then sent a letter giving information about the trial and
the new service and inviting them to participate. Large
print formats of the information were available on
request. The interviewer telephoned patients several days
after receipt of the letter, and arranged to meet them (usu-
ally at home) to explain more about the study and service,
agree consent, ask if the nearest carer/family member
could be approached, and complete the baseline inter-
view.
Table 1: Appraisal of design options for exploratory trial in phase II
Pros Cons
Experimental designs
Traditional randomised controlled trial Gold standard way to understand a difference 
between intervention and control
Concerns regarding recruitment, patients/staff may not 
be willing to take part if some patients do not get 
intervention, some staff had ethical concerns
Cluster randomisation Reduce problem of disappointment of no 
service and contamination
Need extremely large sample and number of clusters, 
analysis required at level of cluster
Patient preference randomisation Makes explicit problem of patients who have 
strong preference for one type of service
Difficult for patients to have a preference when they 
know little about service, large sample size needed, 
potential for staff or others to advise patients to have a 
particular preference
Delayed intervention randomised trial All patients will eventually receive service, uses 
a gold standard methodology, it is common in 
this condition for patients to wait 3 months for 
appointments, longer survival means patients 
likely to actually receive service
Some staff not happy for patients to wait 3 months, 
effect of service must be apparent before 3 months (i.e. 
before control group receive intervention)
Quasi-experimental designs
Geographical comparison No problems of randomisation, potential to 
increase sample size by study in an area where 
no service
Biases involved in variations in service provision 
between areas
Historical controls No problems of randomisation Biases in data collection and potentially in sample 
selection
Matched controls No problems of randomisation Biases in patient selection, difficulty of matching
Observational study No problems of randomisation No comparison group, only comparison with how 
patients were at referral, problems of regression to the 
mean, interviews and inclusion in study may have effect 
in itself.Page 4 of 11
(page number not for citation purposes)
BMC Palliative Care 2006, 5:7 http://www.biomedcentral.com/1472-684X/5/7Inclusion criteria
Patients in South East London who were living with MS
and were deemed (by staff – MS nurses, neurologists,
rehabilitation staff, primary care staff, social workers –
and in a few instances via voluntary groups and self refer-
rals) to have possible palliative care needs. Referrers were
encouraged to identify people as severely affected by MS
based on their clinical need, rather than relying on any
standardised measures of disability. However, since a
large Canadian population study identified that approxi-
mately 15% of people with MS have an Expanded Disabil-
ity Scale Score of 8 or more (out of a possible 10)[26], this
was also suggested to referrers as a benchmark for disabil-
ity that would prompt consideration of referral. Examples
of palliative care needs were given as uncontrolled symp-
toms, psychosocial concerns, advance planning and end
of life issues, progressive illness or complex needs.
Recruitment was aided by awareness of the service being
raised by the service-modelling phase, a service launch,
liaison with voluntary organisations, especially local MS
Society groups, and a programme of educational events.
Exclusion criteria
Those patients deemed as having urgent needs (following
independent review by a consultant in palliative medi-
cine) because of rapid deterioration or severe symptoms
were seen immediately by the service.
Standard best practice
People affected by MS within the study area received a
variety of services. These were available to all those who
received the new palliative care service immediately and
after a delay. Amongst the services available were nurses
(including nurses specialising in MS), physiotherapy,
neurology and rehabilitation services. On average MS spe-
cialist nurses contacted people with MS by telephone at
least once every 6 months, more if patients had greater
need, and visited when appropriate. In addition, district
nurses, social services  and general practitioners provided
support in the community. A few patients received home
physiotherapy, occupational therapy and/or attended spe-
cialist rehabilitation services or clinics. Most had seen a
neurologist within the last 6 months and many were still
under the care of the neurologist, although hospital
attendance as an out-patient was more difficult for those
with severe disability. In-patient care was available as
required, particularly for the treatment of infections,
although this was seldom on wards with specialist knowl-
edge of MS or disability. In-patient rehabilitation was
available to some patients, as were other specialist serv-
ices, including continence advice, psychiatry and/or psy-
chology. Most patients were entitled to some financial
benefits because of their disability, which went towards
their costs of care. Charities such as the MS Society pro-
vided information on available services and organised
support groups. In addition, carers, usually family mem-
bers and friends, supported many patients.
Intervention: the new service
The new service was offered in addition to the standard
best practice services outlined above. It aimed to comple-
ment the existing local services and not to duplicate or
replace them, providing consultation and shared care with
other agencies. It comprised a part-time palliative medi-
cine consultant (who had received training in palliative
medicine and had experience in neurology), a nurse with
immediate experience of working as a nurse specialist in
neurology, and with some palliative care training, a psy-
chosocial worker (also part of the existing palliative care
team), and a service co-ordinator/administrator. Patients
were visited by the service in their own homes, or in some
instances, depending on circumstances, were seen in day
units, rehabilitation centres, nursing homes or in hospital.
After an initial assessment, treatment was recommended
and follow-up occurred as required. The services aimed to
provide a quality comprehensive palliative care assess-
ment and suggest ways to improve management of physi-
cal, emotional, social and other problems, provide
specialist welfare benefits advice and bereavement sup-
port, liaise with and act as a catalyst with local services,
both primary and specialist teams, enable crisis preven-
tion and to develop education and support for primary
and secondary care. During care from the service, those
patients requiring review by a neurologist were referred to
ES (a consultant neurologist based at KCH) and those
requiring ongoing specialist palliative care input were
referred to existing local community or hospital palliative
care teams.
Timing of follow up interviews and receipt of new service
After the baseline interview, details of those patients ran-
domised to fast track were immediately passed to the pal-
liative care service. Those patients randomised to standard
best practice were notified and details were kept with the
research team until after the third research interview at 12
weeks, when details were passed to the clinical team.
Interviews were repeated for both groups at 4–6 weeks,
10–12 weeks, 16–18 weeks (the standard practice group
only, to occur 4–6 weeks after receipt of the palliative care
service) and 24–26 weeks. The timing and procedure is
shown in figure 2.
The interviewers
The interviewers were all trained interviewers from either
social science, nursing or medical backgrounds. All had
previous experience in interviewing in palliative care. Sup-
port for interviewers, if they found the experience diffi-
cult, was offered within the department, either by other
staff and, if required, using external supervision. Because
of the high number of interviews needed at certain timesPage 5 of 11
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interviewers were used at stages of the project. However,
most interviews were conducted by one interviewer.
Trial data collection and outcome measures
Face to face interviews were conducted in the location
most suited to the patient and/or carer, usually home, but
occasionally a care or nursing home. Data collected
included standardised questionnaires recording demo-
graphic, clinical data and cognitive status, and the
patient's functional status (both self report and inter-
viewer assessed[27]) (see table 2). Outcome measures
were selected following a systematic literature review
appraising potential questionnaires[28] and piloting of
candidate measures and whole interview schedule. The
primary outcome measure was palliative care symptoms
as assessed by the POS-MSS, adapted to take account of
symptoms relevant in palliative care and MS[29,30]. Sec-
ondary outcomes included self-reported quality of life
and impact of MS[31,32], psychosocial palliative care out-
comes[29,30], use of health and social services, and expe-
rience of hospital services. Not all questionnaires were
used at every interview (see table 2 for full details). Carers
self-completed a short separate questionnaire assessing
carer burden and mastery, either whilst the patient was
being interviewed, or subsequently, returning the ques-
tionnaire by post. Interviewers usually read out the ques-
tionnaire to patients. The interview process was improved
by showing respondents the potential range of standard
responses to some of the scales, using large print (because
of visual difficulties) laminated A4 sheets (see figure 3 for
an example). We timed a sample of interviews, and
recorded place of interview.
Clinical staff data collection and final survey
In addition, the clinical staff recorded routine clinical data
– demographic, clinical and symptom assessments – on
all patients when seen by the palliative care service,
including those excluded from the trial because of urgent
needs or refusal. At the end of the study we independently
surveyed all patients and carers who had received the serv-
ice using a semi-structured questionnaire to ask about
their experiences and views.
Ethics
The King's College Hospital Research Ethics committee
gave full ethical (IRB) approval for the study. Approval
was obtained separately for the different components of
the study. Following piloting of the questionnaires and
recruitment methods, protocol amendments were made
and approved.
Analysis
The analysis was conducted separately for the different
phases of the study.
1. Qualitative data from interviews and focus groups were
analysed into themes using the constant comparative
approach. Data were initially coded as 'free nodes', and
these were then grouped into broader themes. This infor-
mation was then used to model the service.
2. The trial data were cleaned, checked for coding errors
and entered into SPSS. Initial inspection of the data
checked for discrepancies in coding, and explored pat-
terns of missing data. Using univariate and multivariate
analysis we tested for factors associated with any missing
Timing of interviews and intervention for patients in both fast track and standard best practice groupsF gure 2
Timing of interviews and intervention for patients in both fast track and standard best practice groups.
 
 
Fast track          time 
 
 
 
Standard          time 
 
                     Baseline (B)         B+ 4-6 wks     B+ 12-13 wks     B+ 16-18 wks   B+ 24-26 wks 
 
 
    
= interview undertaken              = First appointment with palliative care service  
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missing data, and conducted all analysis excluding miss-
ing data and also using imputations to check whether
there were differences between the results using different
approaches. We tested for differences between the stand-
ard practice and fast track groups at baseline.
3. Data were then analysed at two time points. First, data
from the fast-track and standard practice groups were
described and compared, plotting the severity of symp-
toms and problems. We tested for significant differences
between fast track and standard best practice at baseline
and at 4–6 weeks (interview 2) and 12 weeks (before the
standard best practice patients received the service, inter-
view 3). We also calculated response scores, computing
both the difference and the ratio between baseline and
interview 2 and interview 3[33]. We then compared these
between our fast track and standard intervention groups.
Second, we described the scores over time in the two
groups, up to interview 5, contrasting the patterns and
change in scores for the standard track group before and
after the intervention, and for the fast track group after the
intervention (up to 24 weeks)[33]. We plan to describe
response scores for patients and families in subgroups, if
possible, for example, according to severity of baseline
problems.
Throughout we used mean (SD), median, mode and
range summary statistics, independent t-tests and paired t-
tests for numerical normally distributed data, and Mann
Whitney U and Wilcoxon Paired Rank Test (for ordered
categorical data) and Chi-Squared tests (for categorical
data)[33]. Spearman (and checked with Pearson) correla-
tions and ANOVA were calculated to test for associations
between degree of missing data and patient or other char-
acteristics.
The trial was designed to be a preliminary phase II trial, to
test design feasibility, recruitment and attrition, to help
model the service for the future and to determine likely
effects. Therefore, a formal sample size calculation was
not essential. However, we estimated that a sample of 25
patients in each group would enable us to detect clinically
significant differences of greater than 1.6 on the Palliative
Outcome Scale (for individual items), where items had a
standard deviation of less than 2, at p < 0.05, power 80%.
Based on the local patient numbers of people with an
EDSS of > 8, we estimated we would identify 3–4 patients
per week, and be able to recruit and follow up 2 of these.
Recruitment over 1 year would therefore give us 50–52
patients, which should give us a sufficient indication
whether differences between groups were emerging.
Data from the final survey and clinical activity were ana-
lysed descriptively to better understand how the new serv-
ices had worked, what work the team had undertaken and
what aspects recipients had found helpful, not helpful
and to record their suggestions for improvement[34].
Results from phase I and service staff recruitment
The results of phase I identified five main concerns for
patients and families; loss and change, support needs
(both emotional and practical), information needs (for
services, aids, adaptations, benefits, and end-of-life plan-
ning), symptom control, and issues concerned with the
delivery of care including co-ordination, continuity, and
problems with inpatient care[35]. The focus groups and
interviews with staff identified two issues similar to those
of patients and a further four issues which were slightly
different (see table 3)[36]. These results led us to model
the service and also to hold awareness raising and educa-
tional events for staff.
Initially a consultant in palliative medicine (RB) was
recruited to the service. She conducted some of the staff
interviews and began a consultation service for patients to
further explore needs and test out methods of working in
palliative care. These patients (25 in total) were not
included in the trial, but were involved in piloting the
questionnaires and recruitment methods. Specialist psy-
chosocial input was obtained from the psychosocial
worker on the generic hospital palliative care team. The
consultant and the psychosocial worker worked part-time
between the MS service and the general palliative care
team. Finally, a clinical nurse specialist and an adminis-
trator working exclusively with the MS service were
appointed and the trial commenced.
Discussion
The MRC framework for the evaluation of complex inter-
ventions has been used to develop and evaluate services
for patients with chronic conditions, including stroke. It
has been proposed as possible in palliative care[37]. How-
ever, a search of Medline from 1966 – July 2006 found no
formal reports of its use in palliative care, hospice care or
terminal care. This study demonstrated how the frame-
work might be used in modelling and evaluating a new
palliative care service. There were several positive aspects
to the approach. The Service Modelling phase gave valua-
ble information on the detail of the structures and proc-
esses of the service, and in addition helped to raise
awareness of the service. There was an opportunity for a
wide range of disciplines, including rehabilitation medi-
cine, neurology, palliative care, professionals allied to
medicine, general practice and various branches of nurs-
ing to feed into the design of the service. We believe this
helped to improve working relationships with other serv-
ices. The local patient data helped to confirm local need
and the precise modelling of the service. In phase II,
embarking on a preliminary evaluation, was, we feel,Page 7 of 11
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randomised controlled trial. The phase II nature of the
trial will allow us to test the feasibility of trial methods,
and the data from this trial will aid selection of design,
measures and calculation of sample sizes for a larger
definitive trial should this be appropriate.
Tilling et al used the MRC Framework to develop a family
support organiser service and to refine outcome measures
for evaluation[38]. After development they progressed
directly to a phase III randomised controlled trial, and the
preclinical and second phases were very limited. Robin-
son et al sought to complete the early phases of the MRC
Framework to facilitate coping skills in new carers of
stroke patients[39]. In the preclinical (theoretical) phase,
a theoretically based framework for a small group course
for carers of people with stroke was developed. The inter-
vention was grounded in a cognitive behavioural model
and included carers' needs identified from a literature
review. Phase I (modelling phase) comprised a qualitative
study involving one-to-one semi-structured interviews
with a purposive sample of informal carers of people with
stroke. Following this, the intervention was modified. In
phase II (exploratory phase), the modified intervention
was delivered by a clinical psychologist and stroke nurse
practitioner to five carers. The course was further refined
and delivered to seven new carers who subsequently com-
pleted a satisfaction questionnaire. As in our study the
MRC framework provided a useful methodology for the
development of a complex intervention.
A criticism of our study is the limited theoretical develop-
ment at the start of pre-clinical modelling. We did model
the service on evidence of other services that helped
patients and families, and on some theoretical constructs,
but this could have been more formally done. However,
the modelling in phase I was more extensive than that of
Tilling et al[38] or Robinson et al[39], compensating for
this deficit. Furthermore, our preliminary evaluation
(phase II) was far more extensive than either of these stud-
ies. Robinson et al interviewed only 12 carers, and Tilling
et al virtually omitted the phase. However, given the diffi-
culty of trials in palliative care [40, 41, 42], and the
number of trials that experience serious problems with
recruitment, attrition and contamination, we feel that a
detailed phase II study was warranted. In the development
of drugs and other therapies, phase I and phase II studies
are often given considerable time and attention, and find-
ings are often published in very high impact factor jour-
nals. It is time, perhaps that such attention is given to
palliative service developments at phase I and II. By intro-
ducing a randomised trial at phase II we will be able to test
the trial method as well as the intervention.
The use of a delayed intervention randomised trial in pal-
liative care is also novel. We are aware of no other study
in palliative care that has used this design. Often this
Table 2: Questionnaires used in the trial. For a full review of measures see [28]
Patient questionnaires
Administered once only
• AMTS (Abbreviated Mental Test Score)
- 10 simple questions used to assess cognitive function
• Structured interview of basic demographic and clinical information
Administered twice (first and last interview)
• UNDS (United Kingdom Neurological Disability Scale) [18]
- 12 sections designed to assess disability in people with MS
• EDSS (Expanded Disability Status Scale) [27]
- 10-point rating scale used to identify level of MS disability
Administered at every interview
• MSIS (Multiple Sclerosis Impact Scale) [31, 32]
- 29 questions on a variety of MS-related symptoms on a 1–5 scale
• POS (Palliative Care Outcome Scale) [29, 30] + POS-MS symptoms
- 10 items on anxiety, patient and carer concerns, practical needs
- 18 questions specifically relating to MS symptoms on a 0–4 scale
• Structured health/social services/demographic interview
- Record of frequency and types of heath/social services received
- Assessment of hospital care if received
Carer/family questionnaires (administered at every interview)
• CBurden (Zarit Carer Burden Inventory)
- 12 questions on carer burden
• Mastery (Lawton caregiver mastery scale)
- 4 items on positive experiences of caringPage 8 of 11
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BMC Palliative Care 2006, 5:7 http://www.biomedcentral.com/1472-684X/5/7approach is not realistic; palliative care patients usually
die so quickly that those in the delayed intervention group
will not receive the intervention. However, the design is
used in rehabilitation studies, and this group of patients
was accustomed to wait for longer periods for outpatient
appointments etc. Therefore, this design was deemed as
appropriate and was acceptable to people with MS, carers
and professionals. We suggest that as palliative care moves
Table 3: Issues raised by health professionals in focus groups and individual interviews when asked
Issues raised which were similar to those from patients - continuity of care
- service delivery
Issues raised which were different to those from patients/families - resources – a concern that expanding palliative care to people affected 
by MS would drain their resources, or divert resources from other fields 
such as rehabilitation medicine
- unpredictability of disease process – being unclear when a referral to 
palliative care would be appropriate, being unsure what to do if patients 
might improve or progress
- mutual lack of knowledge between different specialities
- need for professional training and information exchange
Examples of the laminated questions which patients viewed while the questionnaire was read to themFigure 3
Examples of the laminated questions which patients viewed while the questionnaire was read to them.
In the past two weeks, how much has your MS limited your ability to…
In the past two weeks, how much have you been bothered by…
Not at all A little Moderately Quite a 
bit
Extremely
1 2 3 4 5
SECOND SHEET
How much has the problem in question affected how you have been feeling over the past 
two weeks …
Not at all Slightly Moderately Severely Overwhelmingly
0 1 2 3 4Page 9 of 11
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BMC Palliative Care 2006, 5:7 http://www.biomedcentral.com/1472-684X/5/7forward into non-cancer conditions, where survival is
longer and less easy to predict, this design would be of
value.
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